Unknown Analyst

Bank of America Healthcare Conference in extremely toasty Las Vegas. Ending up our final talk of the day is I'm very pleased to have join us the team from NewAmsterdam. So this is Ian Somaiya and BJ Jones, Chief Commercial Officer. Gentlemen, thank you so much for joining us.

William Jones
Chief Commercial Officer

Pleasure.

Mayur Somaiya
Chief Financial Officer

Yes. Thanks for the invite.

Unknown Analyst

Maybe just to start at a high level for those maybe not as familiar with the NewAmsterdam story. Can you give us a brief overview of the company and obicetrapib?

Mayur Somaiya
Chief Financial Officer

Sure. Look, it's been an exciting couple of years. Obviously, we've shared a lot of data with you from our Phase III studies for both of our lead programs, obicetrapib as well as the combination with ezetimibe. And really, the goal is to help redefine how patients with elevated LDL are being treated today. The data from the Phase III studies has been quite consistent with the monotherapy showing somewhere between a 35% and 40% reduction in LDL. The combination that would benefit that's in the 50% range. And the benefit goes beyond LDL. So that's when I said the opportunities to redefine the care of patients is looking at the LDL plus characteristics of the drug. So it's the roughly 50% reduction in Lp(a). It's the improvements that are driven by the HDL raising profile of the drug, which include the reduction in the rate of new on-set diabetes, the improvement in kidney function that we recently reported at the ACC as well as the early Alzheimer's signal, which we're going to be further exploring in a short order in a